Marta Casal Moura, MD, MSc, MSPH, began her one-year Vasculitis Clinical Research Consortium (VCRC)-Vasculitis Foundation (VF) Fellowship in July 2022. For anti-neutrophil autoantibody (ANCA)-associated vasculitis (AAV), she is studying the predictors of response to plasma exchange in patients who have AAV glomerulonephritis and how histologic scores can predict the response…...
Introducing Our 2023-2024 VCRC-VF Fellow: Roger Yang, MD
Roger Yang, MD, began his Vasculitis Clinical Research Consortium (VCRC)-Vasculitis Foundation (VF) Fellowship in September 2022. Dr. Yang’s training through the Penn Vasculitis Center at the University of Pennsylvania will focus on both clinical care of patients with all forms of vasculitis and research on the diseases. As vasculitis may…...
University of Michigan’s Vasculitis Program: Hoping to Impact Individual Patients and the Approach to the Diseases
Julia Ford, MD (left) and Ora Singer, MD, MS The University of Michigan (U-M) Vasculitis Program began in September 2021 with a soft launch. “We started simply by instituting a dedicated vasculitis clinic and have been moving forward step by step,” said Ora Singer, MD, MS, Director of U-M’s Vasculitis…...
Introducing Our 2022-2023 VCRC-VF Fellow: Mohanad M. Elfishawi, MBBCh, MS
Mohanad M. Elfishawi, MBBCh, MS, began his one-year Vasculitis Clinical Research Consortium (VCRC)-Vasculitis Foundation (VF) Fellowship on January 1, 2022. Dr. Elfishawi will be working on several projects in giant cell arteritis (GCA) including investigating metabolic risk factors for GCA. In addition, he plans to study aortic involvement in patients with…...
Recruiting: A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA)
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper regimen, as measured by the proportion of participants in sustained remission at Week…...
- 1
- 2
